NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Abernethy AP, Allen Lapointe NM, Wheeler JL, et al. Horizon Scan: To What Extent Do Changes in Third-Party Payment Affect Clinical Trials and the Evidence Base? [Internet] Rockville (MD): Agency for Healthcare Research and Quality (US); 2009 Aug 28.
This publication is provided for historical reference only and the information may be out of date.
Horizon Scan: To What Extent Do Changes in Third-Party Payment Affect Clinical Trials and the Evidence Base? [Internet]
Show details| TRIAL NAME | DATE | LOCATION | OBJECTIVE | PI NAME & # |
|---|---|---|---|---|
| CORAL Trial 1 | published 2005 | Multicenter (~100) sites | This study is designed to test the hypothesis that optimal medical therapy with stenting of hemodynamically significant and angiographically documented ARAS in patients with systolic hypertension reduces the incidence of adverse CV and renal events. | Christopher J. Cooper Medical Univ of Toledo, OH ude.ocm@repoocc Coordinator: Holly Burtch ude.odelotu@hctrub.ylloh |
| CORAL Trial 2 | Sep 2003 - ??? | Multicentre intergroup trial | This multicentre phase III CORAL study aims to guide choice of salvage chemotherapy in diffuse large B-cell lymphoma (DLBCL) and assess the role of rituximab maintenance after autologous stem cell transplantation (ASCT). | H. Hagberg Dept of Oncology Akadeniska sjukhuset 75185 Uppsala, Sweden +46 18 611 55 29 es.aksimedaka@grebgah.snah |
| CREST | published 2006 | Multicenter sites | We sought to evaluate resource use, cost, and cost-effectiveness of cilostazol in CREST. | John S. Douglas Director, Interventional Cardiology Emory University Hospital 404-727-7040 gro.erachtlaehyrome@salguod.nhoj Coordinator: Pamela Hyde 404-712-7665 |
| CARESS | published 2005 | 11 centers in France, Germany, Switzerland, & UK | Asymptomatic Microembolic Signals (MES), detected by transcranial Doppler ultrasound (TCD), are markers of future stroke and transient ischemic attack (TIA) risk, offering a surrogate marker to evaluate antiplatelet therapy. This is the first multicenter study to evaluate the feasability of this approach. | Hugh S. Markus Dept. of Clin Neuroscience St. George's Hosp Med Sch Cranner Terrace London, SW17 ORE, UK ku.ca.smhgs@sukram.h |
| SAPPHIRE | Feb 2002 – Jun 2002 | 29 US Centers | The SAPPHIRE trial was a randomised study comparing carotid stenting with the AngioGuard embolic protection device to CEA in patients at increased risk for carotid surgery. | Jay S. Yadav Dept. Cardiovasc. Med The Cleveland Clinic Found 9500 Euclid Ave., F25 Cleveland, OH 44195 |
| Vertebroplasty Trial 1 | published 2002 | Columbus & Toledo, OH | To determine the efficacy and durability of percutaneous vertebroplasty for the treatment of back pain associated with vertebral body compression fractures. | J. Kevin McGraw Dept. Vasc & Intervent. Radiology, Riverside Methodist Hosp 3555 Olentangy River Rd Suite 2050 Columbus, OH 43214 moc.liamtoh@wargcmkj Coordinator: J. Kevin McGraw 614-340-7747 |
| Vertebroplasty Trial 2 | Dec 2001 – Aug 2003 | Fukuchiyama, Kyoto, Japan | To asses the immediate efficacy of percutaneous vertebroplasty (PVP) in relief of pain and improving mobility of patients with vertebral compression fractures (VCF) secondary to osteoporosis. | Kiyokazu Kobayashi Dept. of Radiology Kyoto Renaiss Hosp 1–38 Suehiro-cho, Fulushiyama Kyoto, Japan pj.ssianer@ygoloidar +81-773-223550 |
| Vertebroplasty Trial 3 | Nov 1994 – Jun 2002 | Madrid, Spain | To determine the factors affecting the outcome of percutaneous vertebroplasty for the treatment of persistent painful osteoporotic fractures. | Luis Alvarez Dept. of Orthopaedics Fundacion Jimenez Diaz, Av. Reyes Catolicos, 2, 28040 Madrid, Spain se.djf@zeravlal |
| Vertebroplasty Trial 4 | published 2003 | Washington Univ Med Cnt, St. Louis, MO | To evaluate different types of polymethylmethacrylate (PMMA) leakage and patient-related factors in relations to clinical midterm (1–24 month) outcome after vertebroplasty. | (Corr. Author) Louis A. Gilula Inst. Of Radiology Wash Univ Med Ctr 510 S. Kingshighway Blvd. St. Louis, MO 63110-1076 ude.ltsuw.rim@alulig |
| Vertebroplasty Trial 5 | 1996–1999 | 7 hospitals in US | To describe the immediate outcome of a large cohort of patients who underwent percutaneous polymethylmethacrylate (PMMA) vertebroplasty for treatment of one or more vertebral fractures. | Avery J. Evans Radiology Assoc of Tampa 511 W. Bay St, Suite 301 Tampa, FL 33606 moc.rr.yabapmat@1snavea |
| Early ICD Trial | Jul 1998 – Feb 2003 | 45 centres in Italy | This multicentre prospective randomised trial was undertaken to evaluate the usefulness of an electrophysiological study (EPS) - guided/inplantable cardioverter defibrillator (ICD) strategy in patients at high risk of sudden death (SD) early after myocardial infarction (MI). | Antonio Raviele Cardiology Div. Ospedale Umberto I Via Circonvallazione, 50 - 30170 Mestre-Venezia, Italy +39 041 2607201 ti.nit@leivara |
| MIRACLE ICD Trial | Oct 1999 – Aug 2001 | Multicenter US | To examine the efficacy and safety of combined CRT and ICD therapy in patients with New York Heart Association (NYHA) class III or IV, congestive HF despite appropriate medical management. | James B. Young Cleveland Clinic Found 9500 Euclid Ave, F25 Cleveland, OH 44195 gro.fcc@jgnuoy Coordinator: MEDTRONIC |
| MUSTT Study | 1991 – 1996 | Multicenter German Trial | The multicenter unsustained tachycardia trial (MUSTT) tested the value of electrophysiologically guided antiarrhythmic drug therapy against no therapy in high risk coronary artery disease with poor left ventricle function (LV-EF<=40%) and nonsustained ventricular tachycardia. | Helmut U. Klein Div. of Cardiology University Hosp Leipziger Strasse 44, D 39120 Magdeburg, Germany ++49 391 671 32 03 ed.grubedgam-inu.nizidem@nielK.tumleH |
| B-Blocker + ICD Trial | Jun 1998 - ??? | 95 Centers in Italy & Germany | This trial will test the hypothesis whether, in high-risk poast myocardial infarction (MI) patients already treated with B-blockers, electrophysiologic study (EPS)-guided therapy (including the prophylactic implantation of implantable cardioverter defibrillator [ICD] in inducible patients) will improve survival compared with conventional therapy. | Antonio Raviele Cardiology Div. Ospedale Umberto I Via Circonvallazione, 50 - 30170 Mestre-Venezia, Italy +39 041 2607201 ti.nit@leivara |
- Preliminary List of Clinical Trials - Horizon Scan: To What Extent Do Changes in...Preliminary List of Clinical Trials - Horizon Scan: To What Extent Do Changes in Third-Party Payment Affect Clinical Trials and the Evidence Base?
Your browsing activity is empty.
Activity recording is turned off.
See more...